SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that its stockholders approved all the matters proposed in the Company’s recent proxy statement, including the approval of the sale of AVINZA and related assets to King Pharmaceuticals, Inc. In addition, the Company’s stockholders approved amendments to Ligand’s 2002 stock incentive plan. The results were certified following a Special Meeting of Stockholders held this morning. The Company is working closely with King to formally close the AVINZA sale as quickly as possible.
